Lucid Diagnostics Reports 31% Increase In Quarterly EsoGuard Test Volume With Record 3,174 Tests In Q2 2024
Portfolio Pulse from Benzinga Newsdesk
Lucid Diagnostics reported a 31% increase in quarterly EsoGuard test volume, reaching a record 3,174 tests in Q2 2024.
July 23, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lucid Diagnostics reported a significant 31% increase in the volume of its EsoGuard tests, reaching a record 3,174 tests in Q2 2024. This growth indicates strong demand and could positively impact the company's revenue and stock price.
The 31% increase in EsoGuard test volume suggests strong demand for Lucid Diagnostics' product, which is likely to boost the company's revenue. This positive performance is expected to have a favorable impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100